GLSI Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $7.78 - $34.10

6 Year GLSI Performance Metrics:

Total Return (with DRIP): 261.0% (23.86% CAGR)

Total Return (no DRIP): 261.0% (23.86% CAGR)

Share Price: 261.0% (23.86% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $36,100

Total Return $ (with DRIP): $26,100

GLSI Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

GLSI Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for GLSI

Based on past 6-year performance, here are GLSI growth metrics:

Share price CAGR of +23.86%
Dividend CAGR of +0%

Using GLSI CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	GLSI (DRIP)	GLSI - No DRIP
Current Price	$18.05	$18.05
Start Shares	554.02	554.02
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	554.02	554.02
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$18.05	$18.05
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - GLSI

NOTE: Above numbers are our estimate based on GLSI's Dividend and Price CAGR over past 6 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Greenwich LifeSciences, Inc. (GLSI) had its IPO on , and is traded on NASDAQ stock exchange.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its primary program centers on GP2, an investigational peptide-based immunotherapy designed to help prevent breast cancer recurrence after surgery. The company’s research and clinical activities are concentrated on advancing cancer vaccines and immune-based treatments that target HER2-related disease, a major area in oncology where precision therapies play an important role. Greenwich LifeSciences operates as a biotechnology developer rather than a commercial drug producer, with its current work centered on clinical evaluation, safety, and efficacy of its lead candidates. Based in Stafford, Texas, Greenwich LifeSciences is positioned within the broader life sciences sector as a specialized company addressing unmet needs in post-treatment breast cancer care.

GLSI website: https://greenwichlifesciences.com